ライフサイエンスコーパス: lactis

1 ined the ability to uptake (3)H-biotin by L. lactis.

2 genes present in the probiotic bacterium L. lactis.

3 The construct was introduced into L lactis.

4 st in a culture of the bacterium Lactococcus lactis.

5 ng type a (MATa) to MATalpha in the yeast K. lactis.

6 lus bulgaricus, and Lactococcus lactis subsp Lactis.

7 omodimeric multidrug ABC transporter from L. lactis.

8 n-specific S component BioY from Lactococcus lactis.

9 intranasally with Shr-expressing Lactococcus lactis.

10 udied Sir2 from another yeast, Kluyveromyces lactis.

11 derived from the budding yeast Kluyveromyces lactis.

12 d expressed this fusion protein (MBP*) in L. lactis.

13 milar to the nisin-A produced by Lactococcus lactis.

14 the unicellular budding yeast Kluyveromyces lactis.

15 iod (SCORAD-score pre-/post-intervention: B. lactis 25.9 [95% CI: 22.8-29.2] to 12.8 [9.4-16.6]; L. p

16 ate that, in the budding yeast Kluyveromyces lactis, a DNA rearrangement associated with mating type

17 amily of Siphoviridae and infect Lactococcus lactis, a gram-positive bacterium used in commercial dai

18 chored in the outer cell wall of Lactococcus lactis, a Gram-positive surrogate that otherwise lacks a

19 Lactococcus lactis, a non-pathogenic bacteria, has been genetically

20 In a relatively recent ancestor of K. lactis, a reorganization occurred.

21 us Sfp transferase required to modify the L. lactis AcpA and the chimera of L. lactis AcpA helix II i

22 pP helix II was due to incompatibility of L. lactis AcpA helix I with the downstream elements of AcpP

23 Expression of the AcpP protein L. lactis AcpA helix II allowed weak growth, whereas the L.

24 ify the L. lactis AcpA and the chimera of L. lactis AcpA helix II in AcpP).

25 Replacement of the L. lactis AcpA helix II residues in this protein showed tha

26 s showed that the lack of function of the L. lactis AcpA-derived protein containing E. coli AcpP heli

27 helix II allowed weak growth, whereas the L. lactis AcpA-derived protein that contained E. coli AcpP

28 homologous KLLA0A09713 gene of Kluyveromyces lactis allow for cross-complementation of the respective

29 roorotate dehydrogenases from E. coli and L. lactis also have a lysine near N5 of the flavin.

30 Expression of the recombinant protein in L. lactis also markedly increased biofilm formation.

31 ited by 50% CFS of Lactococcus lactis subsp. lactis and 25% CFS of Leuconostoc lactis. subsp. cremori

32 to divergent yeasts, including Kluyveromyces lactis and alternative S. cerevisiae strains.

33 tosidases (Bacillus circulans, Kluyveromyces lactis and Aspergillus oryzae) was analysed in detail, a

34 dases from Bacillus circulans, Kluyveromyces lactis and Aspergillus oryzae.

35 tions from Aspergillus oryzae, Kluyveromyces lactis and Bacillus circulans.

36 tidrug-proton antiporter LmrP in Lactococcus lactis and developed a novel assay for the direct quanti

37 However, the AcpAs of Lactococcus lactis and Enterococcus faecalis were inactive.

38 e cytoplasm of Escherichia coli, Lactococcus lactis and Haloferax volcanii.

39 This effect is weaker in L. lactis and Hfx.

40 as previously observed for the Kluyveromyces lactis and human telomerase RNA pseudoknots.

41 of PIC2 Additionally, assays in Lactococcus lactis and in reconstituted liposomes directly demonstra

42 ere synthesized with optimal codon use for L lactis and joined with a linker; a signal sequence was a

43 Start, composed by Lactococcus lactis subsp. lactis and L. lactis subsp. cremoris (R704); QLA - with

44 Microbiological (Lactococcus lactis and Lactobacillus acidophilus counts, and functio

45 were identified in Lactococcus lactis subsp. lactis and Lactococcus cremoris subsp.

46 were identified in Lactococcus lactis subsp. lactis and Lactococcus cremoris subsp. cremoris.

47 a monocytogenes, following Lc. lactis subsp. lactis and Leuconostoc mesenteroides subsp. cremoris (20

48 n centromeric nucleosome assembly between K. lactis and S. cerevisiae, we determined the structure of

49 carboxylic acid production by Kluyveromyces lactis and Saccharomyces cerevisiae during two different

50 (~25 bp) are conserved between Kluyveromyces lactis and Saccharomyces cerevisiae, but CDEII in the fo

51 In Lactococcus lactis and Staphylococcus carnosus, the ilvE gene produc

52 ces cerevisiae were expressed in Lactococcus lactis and studied in inside-out membrane vesicles and i

53 es cerevisiae, the dairy yeast Kluyveromyces lactis and the human pathogen Candida albicans.

54 rying from 48.3% (B. circulans) to 34.9% (K. lactis), and 19.5% (A. oryzae).

55 acteria Pseudomonas fluorescens, Lactococcus lactis, and 4 strains of the entomopathogen Bacillus thu

56 ies (Saccharomyces cerevisiae, Kluyveromyces lactis, and Debaryomyces hansenii) are remarkably hetero

57 idge, such as Lactococcus casei, Lactococcus lactis, and Enterococcus faecium.

58 illus casei genome, expressed in Lactococcus lactis, and functionally characterized.

59 m the bacteria Escherichia coli, Lactococcus lactis, and Streptomyces griseus.

60 Unlike the scenario in E. coli, L. lactis appears to be auxotrophic for biotin in that it l

61 CD3 with a clinical-grade self-containing L. lactis, appropriate for human application, secreting hum

62 ese findings show that certain strains of L. lactis are well adapted for growth on plants and possess

63 ted with the intake of probiotic Lactococcus lactis as tolerogenic adjuvant (combined therapy).

64 lacebo group, n = 365) or B. animalis subsp. lactis at a dose of 10(9) colony-forming units/d (interv

65 s containing Bifidobacterium animalis subsp. lactis (B. lactis) HN019 was topically administered in t

66 e genomes of Bifidobacterium animalis subsp. lactis B420 and Bi-07.

67 The collision events of single Lactococcus lactis bacteria at Pt disk ultramicroelectrodes (UMEs) w

68 rehalose ensures the highest viability of L. lactis bacteria upon both drying techniques (viability o

69 ge 340, a 936-type Lactococcus lactis subsp. lactis bacteriophage.

70 ially be used in the future to tailor the L. lactis-based combination therapy for individual patients

71 ment of the immune changes induced by the L. lactis-based therapy revealed elevated frequencies of CD

72 mnosus GG and Bifidobacterium animalis subsp lactis BB-12 (total cell count per capsule, 1.3 x 1010 t

73 philus LA-5, Bifidobacterium animalis subsp. lactis BB-12 and Propionibacterium jensenii 702.

74 mnosus GG and Bifidobacterium animalis subsp lactis BB-12 did not significantly reduce antibiotic adm

75 ay, plus Bifidobacterium animalis subspecies lactis BB-12; n = 55) or placebo (n = 49) for 10-14 mont

76 ); QB - with Bifidobacterium animalis subsp. lactis (BB 12); and QC, co-culture with the three probio

77 hamnosus strain GG [LGG] and Bifidobacterium lactis Bb12 [Bb12]), mimicking gut commensals in breastf

78 nd probiotic, Bfidobacterium animalis subsp. lactis (Bb12) (final dose verified at 10(5) colony formi

79 us acidophilus BCMC(R) 12,130, Lactobacillus lactis BCMC(R) 12,451, Lactobacillus casei subsp BCMC(R)

80 luated the saponins effects on Kluyveromyces lactis beta-galactosidase activity and correlated these

81 tive effects of tannic acid on Kluyveromyces lactis beta-galactosidase catalytic activity and correla

82 of lactose hydrolysis by the immobilized K. lactis beta-galactosidase using genipin as a crosslinker

83 (v/v), the maximum GOS concentration with K. lactis beta-galactosidase was achieved in 1 and 5h at 40

84 sidases, and at 95% lactose depletion for K. lactis beta-galactosidase.

85 The in vivo function of the two L. lactis birA genes was judged by their abilities to compl

86 he probiotic Bifidobacterium animalis subsp. lactis Bl-04 binds alpha-(1,6)-linked glucosides and gal

87 vatus was out-competed by B. animalis subsp. lactis Bl-04 in mixed cultures growing on raffinose, the

88 osidase from Bifidobacterium animalis subsp. lactis Bl-04.

89 P expression was required for survival of L. lactis but not S. pyogenes.

90 rokaryotic PC4-like protein from Lactococcus lactis, but the underlying mechanism remains unclear.

91 h levels in ATL, indicating redundancy in L. lactis carbohydrate metabolism on plant tissues.

92 multidrug transporter LmrP from Lactococcus lactis catalyses drug efflux in a membrane potential and

93 evisiae, we determined the structure of a K. lactis CBF3 complex by electron cryomicroscopy at ~4 ang

94 By testing a panel of L. lactis cell wall mutants, we observed that Lc-Lys and Lc

95 In Lactococcus lactis, cell-wall polysaccharides (CWPSs) act as recepto

96 Furthermore, such piliated L. lactis cells evoked a higher TNF-alpha response during m

97 icient in binding fluid-phase gp-340, and L. lactis cells expressing AspA were not agglutinated by gp

98 accordance with the growth rate, provides L. lactis cells the means to ensure optimal CW plasticity w

99 Ndc10 and discuss potential models of the K. lactis centromeric nucleosome that account for the exten

100 lus paracasei CNCM I-2116 or Bifidobacterium lactis CNCM I-3446 had a treatment effect or altered all

101 e current transients had step shapes when L. lactis collided and adsorbed and spike shapes when they

102 ression of AspA protein on the surface of L. lactis conferred biofilm-forming ability.

103 xpression of the gene product in Lactococcus lactis conferred the ability to adhere to VK2 cells, to

104 ce of the non-adherent bacterium Lactococcus lactis confers adherence to scavenger receptor gp340, hu

105 when expressed on surrogate host Lactococcus lactis, confers binding to immobilized salivary agglutin

106 Here we construct synthetic Lactococcus lactis consortia and mathematical models to elucidate th

107 l level, associated with response to this B. lactis-containing fermented milk product, and therefore

108 h of TP901-1, a bacteriophage of Lactococcus lactis, controlled by the CI repressor and the modulator

109 associated, putative hydrolases, Lactococcus lactis CsiA, Tn925 Orf14, and pIP501 TraG, partially com

110 When we used L. lactis-derived PfCSP4/38 to immunize mice, it elicited h

111 t containing Bifidobacterium animalis subsp. lactis DN-173 010 strain.

112 emented with Bifidobacterium animalis subsp. lactis DN-173010 versus a placebo yogurt, followed by a

113 of the non-pathogenic bacterium Lactococcus lactis during a human whole blood killing assay in a dos

114 plant habitat-specific traits of Lactococcus lactis during growth in an Arabidopsis thaliana leaf tis

115 ntrolling the amount of Y. lipolytica and K. lactis during production offers potential to manipulate

116 ure of Lb. plantarum with acid-producing Lc. lactis enhanced acid and alcohol production, whereas co-

117 RL2010 appendages in nonpiliated Lactococcus lactis enhanced adherence to human enterocytes through e

118 els inoculated with low concentrations of K. lactis exhibited blue cheese-related attributes, associa

119 either 0.035 or 0.1 mM KCl confirmed that L. lactis experienced transport by convection due to electr

120 s demonstrate that oral immunization with L. lactis expressing an Ag on the tip of the group A Strept

121 on the surface of S. aureus- or Lactococcus lactis-expressing FnBPB could be activated to the potent

122 A heterologous Lactococcus lactis expression system was used to express SdrF and it

123 38 NANP repeats) produced in the Lactococcus lactis expression system.

124 Velocities of L. lactis extracted from correlated microscopy movies colle

125 acidophilus, Bifidobacterium animalis subsp lactis, Faecalibacterium prausnitzii, Bacteroides vulgat

126 tudy show that the use of B. animalis subsp. lactis failed to prevent nosocomial infections in an acu

127 c tests in yeast and produced in Lactococcus lactis for further biochemical characterizations using p

128 r) 13(-/-) BMDCs showed a weak response to L lactis G121 and were unresponsive to its RNA.

129 ecule expression, and T-cell activation on L lactis G121 challenge.

130 attern recognition receptors through which L lactis G121 confers allergy protection.

131 In mice L lactis G121 RNA signals through TLR13; however, the most

132 d by TLR8-specific inhibitors, mediated by L lactis G121 RNA, and synergistically enhanced by activat

133 We examined the ability of Lactococcus lactis G121 to prevent allergic inflammatory reactions.

134 In vivo allergy protection mediated by L lactis G121 was dependent on endosomal acidification in

135 L lactis G121-induced cytokine release and surface express

136 Bacterial RNA is the main driver of L lactis G121-mediated protection against experimentally i

137 The TH1-polarizing activity of L lactis G121-treated human DCs was blocked by TLR8-specif

138 L lactis G121-treated murine BMDCs and human moDCs release

139 n mice of biologically contained Lactococcus lactis genetically modified to secrete the whole proinsu

140 ified a potential flippase encoded in the L. lactis genome (llnz_02975, cflA) and confirmed that it p

141 (RNP) complex formed between the Lactococcus lactis group II intron and its self-encoded LtrA protein

142 work, we have trapped the native Lactococcus lactis group II intron RNP complex in its precursor form

143 For the pRS01 plasmid-encoded Lactococcus lactis group II intron, Ll.LtrB, splicing enables expres

144 nce of specific plant-inducible genes for L. lactis growth in ATL, xylose metabolism was targeted for

145 s via the gut through Lactococcus lactis (L. lactis) has been demonstrated to be a promising approach

146 , chimeric ACPs were constructed in which L. lactis helix II replaced helix II of E. coli AcpP and vi

147 oduced using Bifidobacterium animalis subsp. lactis HN019 in co-culture with Streptococcus thermophil

148 Topical use of B. lactis HN019 promotes a protective effect against alveol

149 g Bifidobacterium animalis subsp. lactis (B. lactis) HN019 was topically administered in the subgingi

150 ed a domesticated transposase, Kluyveromyces lactis hobo/Activator/Tam3 (hAT) transposase 1 (Kat1), o

151 ys against the indicator strains Lactococcus lactis HP and Bacillus subtilis 6633.

152 ved MIC values against liquid cultures of L. lactis HP.

153 L. lactis HR279 and JHK24 demonstrates two datasets with an

154 Lactococcus lactis HR279 and JHK24 strains expressing high or low le

155 the 3.0-A crystal structure of Kluyveromyces lactis Hsv2, which shares significant sequence homologie

156 c analyses, we identified genes unique to L. lactis I-1631 involved in oxygen respiration.

157 L. lactis I-1631 may represent a promising vehicle to deliv

158 L. lactis I-1631 possesses genes encoding enzymes that deto

159 s used in the FMP, we found that Lactococcus lactis I-1631 was sufficient to ameliorate colitis.

160 Inactivation of the sodA gene abolished L. lactis I-1631's beneficial effect in the T-bet(-/-) Rag2

161 h in ATL than the dairy-associated strain L. lactis IL1403.

162 ion of beta-galactosidase from Kluyveromyces lactis in Aerosol-OT water-in-isooctane microemulsions w

163 d to the ribosome of the yeast Kluyveromyces lactis in both the canonical and rotated states at overa

164 the cheese supplemented with Bifidobacterium lactis in its isolated form showed the highest proteolyt

165 analysis indicating beneficial effects of B. lactis in particular.

166 the role of Bifidobacterium animalis subsp. lactis in preventing nosocomial infections in the acute

167 when co-cultured with non-acid producing Lc. lactis in the presence of salt.

168 rowth of VRE is inhibited by BP(SCSK) and L. lactis in vitro, only BP(SCSK) colonizes the colon and r

169 s co-inoculation with non-acid producing Lc. lactis increased acetoin synthesis.

170 le to therapy results with plasmid-driven L. lactis Initial blood glucose concentrations (<350 mg/dL)

171 ng: unlike S. cerevisiae and C. albicans, K. lactis integrates nutritional signals, by means of Rme1,

172 hosphoglucomutase (betaPGM) from Lactococcus lactis is a phosphoryl transfer enzyme required for comp

173 The engineered L. lactis is able to develop biofilms on different surfaces

174 and the enzyme from the yeast Kluyveromyces lactis is most widely used.

175 The aspartate pool in L. lactis is negatively regulated by c-di-AMP, and high asp

176 s-specific as Acm2 purified from Lactococcus lactis is not glycosylated.

177 actobacillus rhamnosus 1937, and Lactococcus lactis JBB 500 were enriched with magnesium ions using P

178 nduction of those genes corresponded with L. lactis KF147 nutrient consumption and production of meta

179 L. lactis KF147, a strain originally isolated from plants,

180 charomyces cerevisiae (Sc) and Kluyveromyces lactis (Kl).

181 autoantigens via the gut through Lactococcus lactis (L. lactis) has been demonstrated to be a promisi

182 positions in four other yeasts-Kluyveromyces lactis, Lachancea kluyveri, Lachancea waltii and Schizos

183 ium spp, Bifidobacterium animalis subspecies lactis, Lactobacillus reuteri, or Lactobacillus rhamnosu

184 Lactobacillus sanfranciscensis, Lactococcus lactis, Lactococcus piscium, Lactococcus plantarum, Leuc

185 re model cheeses inoculated with Lactococcus lactis LD61.

186 tococcus lactis LDH2 < E. faecalis LDH1 < L. lactis LDH1 </= Streptococcus pyogenes LDH.

187 of S. pyogenes LDH, E. faecalis LDH1, and L. lactis LDH1 and LDH2 at pH 6.

188 : Enterococcus faecalis LDH2 </= Lactococcus lactis LDH2 < E. faecalis LDH1 < L. lactis LDH1 </= Stre

189 Here, we show that the Lactococcus lactis Ll.LtrB group II intron splices accurately and ef

190 elivery technology based on live Lactococcus lactis (LL) bacteria for controlled secretion of the T1D

191 OD mice were orally treated with Lactococcus lactis (LL) expressing CFA/I.

192 situ by the food-grade bacterium Lactococcus lactis (LL-IL-27), and tested its ability to reduce coli

193 In L. lactis, LlPC is required for efficient milk acidificatio

194 ture of substrate binding within Lactococcus lactis LmrP, a prototypical multidrug transporter of the

195 uperfamily transporter LmrP from Lactococcus lactis mediates protonmotive-force dependent efflux of a

196 The chromosome of Lactococcus lactis MG 1363 contains a 60 kb conjugative element call

197 an gut metagenomic library using Lactococcus lactis MG1363 as heterologous host.

198 he tip of pili external to the surface of L. lactis might constitute a successful vaccine strategy.

199 eport the crystal structure of Kluyveromyces lactis MIND and examine its partner interactions, to und

200 -L-Lys(3); moreover, they do not lyse the L. lactis mutant containing only the nonamidated D-Asp cros

201 In Kluyveromyces lactis mutants lacking telomerase, recombinational telom

202 Two candidate probiotics, Lactococcus lactis NCC 2287 and Bifidobacterium lactis NCC 2818, wer

203 In this EoE model, supplementation with L. lactis NCC 2287 significantly decreased esophageal and b

204 Supplementation with another probiotic, B. lactis NCC 2818, had no significant effect on esophageal

205 tococcus lactis NCC 2287 and Bifidobacterium lactis NCC 2818, were tested in a murine model of EoE el

206 ism were further modified by Bifidobacterium lactis NCC2818 supplementation, although composition of

207 producing and non-acid producing Lactococcus lactis NCIMB 9918 in UHT milk at 30 & 18 degrees C for 4

208 Genetically modified Lactococcus lactis, non-pathogenic bacteria expressing the FNIII(7-1

209 pressed in the heterologous host Lactococcus lactis NZ9000, and the benefits of the newly acquired pa

210 Yarrowia lipolytica and Kluyveromyces lactis occur as part of Stilton cheese microflora yet ar

211 ee such systems in the bacterium Lactococcus lactis On the basis of sequence similarities, we first i

212 the single-species product B animalis subsp lactis or L reuteri significantly reduced duration of ho

213 ound no benefit from supplementation with B. lactis or L. paracasei in the treatment of eczema, when

214 ly supplements containing L. paracasei or B. lactis or placebo for a 3-month period, while receiving

215 nal studies on the inhibition of Lactococcus lactis PC (LlPC) by c-di-AMP.

216 le synthetic circuits can direct Lactococcus lactis populations to form programmed spatial band-pass

217 Here we report that Lactococcus lactis possesses two different orthologues of birA (birA

218 n of protective blends for manufacture of L. lactis probiotic powders was optimized using a statistic

219 Lactococcus lactis produces the lantibiotic nisin, which is widely u

220 terologous expression of SdrD in Lactococcus lactis promoted bacterial survival in human blood.

221 cerevisiae) and in the bacterium Lactococcus lactis Protein production in these two microbial hosts w

222 the intestinal bacterium B. animalis subsp. lactis provide insights into rapid genome evolution and

223 solution NMR structure of the Kluyveromyces lactis pseudoknot, presented here, reveals that it conta

224 d transients that occurred when colliding L. lactis reduced transport of FcM to the electrode.

225 ation and that LTA galactosylation alters L. lactis resistance to bacteriocin.

226 Increasing the inoculum concentration of K. lactis resulted in decreased variation between replicate

227 eport the crystal structure of Kluyveromyces lactis Rtr1, which reveals a new type of zinc finger pro

228 odule, and an endochitinase from Lactococcus lactis show that the nonprocessive enzymes have more fle

229 ith recombinant PG overproducing Lactococcus lactis showed limited direct contribution of microbial P

230 . mes. subsp. cremoris and Lc. lactis subsp. lactis showed stimulator effects (160%).

231 s in the Gram-positive bacterium Lactococcus lactis showed that heme exposure strongly induced expres

232 terologous expression of Pic2 in Lactococcus lactis significantly enhanced CuL transport into these c

233 0.27, 0.82), and this was significant for B. lactis (SMD: +0.46; 95% CI: 0.08, 0.85) but not for L. c

234 s and of a mutant of the yeast Kluyveromyces lactis specifically defective in the transport of UDP- N

235 ing plasmid pEW104 isolated from Lactococcus lactis ssp. cremoris W10.

236 r antimicrobial activity against Lactococcus lactis, Staphylococcus aureus, Listeria monocytogenes, a

237 In contrast to the parent L. lactis strain (lacks SpyCEP), which was avirulent when a

238 Mucosal immunization of mice with this L. lactis strain expressing pilus-linked MBP* results in pr

239 Wild-type L. lactis strain KF147 but not an xylA deletion mutant was

240 We used L. lactis strain to colonize material surfaces and produce

241 rast, a strong benefit for the engineered L. lactis strain was observed in acid stress survival.

242 However, Lactococcus latics subsp. lactis strain X and Lactobacillus casei strain B extract

243 We identified a L. lactis strain, able to attenuate esophageal eosinophilic

244 n plasmid pJW566 and can protect Lactococcus lactis strains against bacteriophage infections in milk

245 al evolution of several isogenic Lactococcus lactis strains demonstrated the existence of a tradeoff

246 lysis of two Bifidobacterium animalis subsp. lactis strains revealed evolution by internal deletion o

247 Mice were then infected with Lactococcus lactis strains that differed only in SpyCEP expression.

248 ly sequenced Bifidobacterium animalis subsp. lactis strains, BL-04 and DSM 10140, to hydrogen peroxid

249 ve H(2)O(2) resistance in B. animalis subsp. lactis strains.

250 MPP contained Bifidobacterium animalis subsp Lactis, Streptococcus thermophiles, Lactobacillus bulgar

251 ted with 1 x 10(9) colony-forming units of L lactis subsp cremoris ATCC 19257 or Lactobacillus rhamno

252 Mice fed the L lactis subsp cremoris had increased glucose tolerance wh

253 Dietary supplementation with L lactis subsp cremoris in female mice on a high-fat, high

254 L lactis subsp cremoris is safe for oral ingestion and mig

255 Mice fed L lactis subsp cremoris while on the Western-style diet ga

256 Hepatic lipid profiles of L lactis subsp cremoris-supplemented mice were characteriz

257 s, Lactobacillus bulgaricus, and Lactococcus lactis subsp Lactis.

258 d by Lactococcus lactis subsp. lactis and L. lactis subsp. cremoris (R704); QLA - with Lactobacillus

259 uction of two starter strains of Lactococcus lactis subsp. cremoris (strains from the Culture Collect

260 eroides subsp. jonggajibkimchii, Lactococcus lactis subsp. cremoris, Lactobacillus coryniformis subsp

261 was also inhibited by 50% CFS of Lactococcus lactis subsp. lactis and 25% CFS of Leuconostoc lactis.

262 with culture Start, composed by Lactococcus lactis subsp. lactis and L. lactis subsp. cremoris (R704

263 hyl-1-butanol were identified in Lactococcus lactis subsp. lactis and Lactococcus cremoris subsp.

264 hyl-1-butanol were identified in Lactococcus lactis subsp. lactis and Lactococcus cremoris subsp. cre

265 5%) by Listeria monocytogenes, following Lc. lactis subsp. lactis and Leuconostoc mesenteroides subsp

266 ructure of phage 340, a 936-type Lactococcus lactis subsp. lactis bacteriophage.

267 25% CFS of Leu. mes. subsp. cremoris and Lc. lactis subsp. lactis showed stimulator effects (160%).

268 Recombinant HPP from Lactococcus lactis subsp. lactis that was expressed in Escherichia c

269 ffects of 50% CFS of S. thermophilus and Lc. lactis subsp. lactis were more than 70% by Staphylococcu

270 human isolates and S. pseudoporcinus subsp. lactis subsp. nov. for the dairy isolates.

271 tis subsp. lactis and 25% CFS of Leuconostoc lactis. subsp. cremoris.

272 We assessed the effects of Lactococcus lactis subspecies (subsp) cremoris on weight gain, liver

273 arrant further consideration of using the L. lactis system for the production of circumsporozoite pro

274 This indicates that K. lactis telomeres have preferred termination points withi

275 We further demonstrate that K. lactis telomeric fragments produce banded patterns with

276 se triples, the 3D shape of the human and K. lactis TER pseudoknots are remarkably similar.

277 amily multidrug transporter from Lactococcus lactis that mediates the efflux of cationic amphiphilic

278 combinant HPP from Lactococcus lactis subsp. lactis that was expressed in Escherichia coli contained

279 For L. lactis, the particle velocity due to convection driven b

280 In the yeast Kluyveromyces lactis, the telomerase RNA (Ter1) template has 30 nucleo

281 such as the stn1-M1 mutant of Kluyveromyces lactis, the telomeres appear to be continuously unstable

282 ced into the commensal bacterium Lactococcus lactis, the truncated CBD is also produced, showing that

283 The use of Lactococcus lactis to deliver a chosen antigen to the mucosal surfac

284 s, and we transfer the system to Lactococcus lactis to establish its broad functionality in bacteria.

285 ation with a probiotic organism, Lactococcus lactis, to elicit HIV-specific immune responses in the m

286 Lactococcus lactis transformed with plasmids expressing SpsD and Sps

287 ed microscopy of collision experiments of L. lactis using a 5 mum radius Pt disk UME in 2 mM ferrocen

288 fect the Gram-positive bacterium Lactococcus lactis using receptor-binding proteins anchored to the h

289 f SfbA in the noninvasive strain Lactococcus lactis was sufficient to promote fibronectin binding and

290 intenance of this equilibrium in Lactococcus lactis, we isolated mutants that are resistant to the PG

291 tans, Staphylococcus aureus, and Lactococcus lactis were examined for functional complementation of a

292 CFS of S. thermophilus and Lc. lactis subsp. lactis were more than 70% by Staphylococcus aureus compa

293 found that Orc1 from the yeast Kluyveromyces lactis, which diverged from S. cerevisiae before the dup

294 g the KlCYC1 gene of the yeast Kluyveromyces lactis, which includes a single promoter and two poly(A)

295 Nkp1 and Nkp2, from the yeast Kluyveromyces lactis, with nanoflow electrospray ionization mass spect

296 Models of Y. lipolytica and K. lactis, with Penicillium roqueforti, were analysed using

297 ome of Lactobacillus reuteri and Lactococcus lactis without selection at frequencies ranging between

298 and this was significant for Bifidobacterium lactis (WMD: 1.5 bowel movements/wk; 95% CI: 0.7, 2.3 bo

299 Lactococcus lactis YdbC is a representative of DUF2128.

300 Here, we characterize the Lactococcus lactis yybP-ykoY orphan riboswitch as a Mn(2+)-dependent